Association between CCR5 promoter polymorphisms and hepatitis B virus infection

Hye Young Chang, SangHoon Ahn, doyoung kim, Jeon Soo Shin, Yong Soo Kim, Sun Pyo Hong, Hyun Jae Chung, Soo Ok Kim, Wang Don Yoo, KwangHyub Han

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

BACKGROUND/AIMS: Immunogenetic factors may play a role in determining the susceptibility of an individual to viral infection. CCR5 promoter polymorphisms are known to be associated with HIV infection. However, there has been no report on the association between CCR5 promoter polymorphism and HBV infection. Therefore, we investigated the relationship between the CCR5 promoter polymorphism and HBV infection. METHODS: A total of 377 patients were classified into two groups according to their HBV infection status: (1) the spontaneous clearance group (SC); HBsAg (-), anti-HBc (+), anti-HBs (+) (2) the chronic HBsAg (+) carrier group (CC); HBsAg (+), anti-HBc (+), anti-HBs (-). CCR5 polymorphisms were detected by employing matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS)- based SNP scoring assay, termed Restriction Fragment Mass Polymorphism (RFMP), which exploits the differences in molecular masses between the common allele and rare allele bases of interest. RESULTS: We found that the genotype frequencies of CCR5 A59029G significantly differed between the SC group (n=138) and CC group (n=239) (P<0.05). The CCR5 59029A allelic genotype was associated with an increased risks of chronic infection rather than spontaneous clearance (P=0.002), and the presence of the CCR5 59029G allele was significantly associated with the spontaneous clearance of HBV (P=0.001). Strong linkage disequilibrium between the CCR5-59029 and the CCR5-59353 polymorphic variants was identified. None of the 377 subjects had the CCR5-32 bp deletion mutation. CONCLUSIONS: The CCR5 promoter polymorphisms at position 59029 might play a role in the clearance of HBV infection. This primary experimental evidence needs further studies to clarify the clinical usefulness of CCR5 promoter polymorphisms as a target for the screening or treatment of HBV infection.

Original languageEnglish
Pages (from-to)116-124
Number of pages9
JournalThe Korean journal of hepatology
Volume11
Issue number2
Publication statusPublished - 2005 Jan 1

Fingerprint

Virus Diseases
Hepatitis B virus
Hepatitis B Surface Antigens
Infection
Alleles
Genotype
Immunogenetics
Sequence Deletion
Linkage Disequilibrium
HIV Infections
Single Nucleotide Polymorphism
Mass Spectrometry
Lasers

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Chang, Hye Young ; Ahn, SangHoon ; kim, doyoung ; Shin, Jeon Soo ; Kim, Yong Soo ; Hong, Sun Pyo ; Chung, Hyun Jae ; Kim, Soo Ok ; Yoo, Wang Don ; Han, KwangHyub. / Association between CCR5 promoter polymorphisms and hepatitis B virus infection. In: The Korean journal of hepatology. 2005 ; Vol. 11, No. 2. pp. 116-124.
@article{12b045b92469478da3f79c93214246cd,
title = "Association between CCR5 promoter polymorphisms and hepatitis B virus infection",
abstract = "BACKGROUND/AIMS: Immunogenetic factors may play a role in determining the susceptibility of an individual to viral infection. CCR5 promoter polymorphisms are known to be associated with HIV infection. However, there has been no report on the association between CCR5 promoter polymorphism and HBV infection. Therefore, we investigated the relationship between the CCR5 promoter polymorphism and HBV infection. METHODS: A total of 377 patients were classified into two groups according to their HBV infection status: (1) the spontaneous clearance group (SC); HBsAg (-), anti-HBc (+), anti-HBs (+) (2) the chronic HBsAg (+) carrier group (CC); HBsAg (+), anti-HBc (+), anti-HBs (-). CCR5 polymorphisms were detected by employing matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS)- based SNP scoring assay, termed Restriction Fragment Mass Polymorphism (RFMP), which exploits the differences in molecular masses between the common allele and rare allele bases of interest. RESULTS: We found that the genotype frequencies of CCR5 A59029G significantly differed between the SC group (n=138) and CC group (n=239) (P<0.05). The CCR5 59029A allelic genotype was associated with an increased risks of chronic infection rather than spontaneous clearance (P=0.002), and the presence of the CCR5 59029G allele was significantly associated with the spontaneous clearance of HBV (P=0.001). Strong linkage disequilibrium between the CCR5-59029 and the CCR5-59353 polymorphic variants was identified. None of the 377 subjects had the CCR5-32 bp deletion mutation. CONCLUSIONS: The CCR5 promoter polymorphisms at position 59029 might play a role in the clearance of HBV infection. This primary experimental evidence needs further studies to clarify the clinical usefulness of CCR5 promoter polymorphisms as a target for the screening or treatment of HBV infection.",
author = "Chang, {Hye Young} and SangHoon Ahn and doyoung kim and Shin, {Jeon Soo} and Kim, {Yong Soo} and Hong, {Sun Pyo} and Chung, {Hyun Jae} and Kim, {Soo Ok} and Yoo, {Wang Don} and KwangHyub Han",
year = "2005",
month = "1",
day = "1",
language = "English",
volume = "11",
pages = "116--124",
journal = "Clinical and molecular hepatology",
issn = "2287-2728",
publisher = "Korean Association for the Study of the Liver",
number = "2",

}

Chang, HY, Ahn, S, kim, D, Shin, JS, Kim, YS, Hong, SP, Chung, HJ, Kim, SO, Yoo, WD & Han, K 2005, 'Association between CCR5 promoter polymorphisms and hepatitis B virus infection', The Korean journal of hepatology, vol. 11, no. 2, pp. 116-124.

Association between CCR5 promoter polymorphisms and hepatitis B virus infection. / Chang, Hye Young; Ahn, SangHoon; kim, doyoung; Shin, Jeon Soo; Kim, Yong Soo; Hong, Sun Pyo; Chung, Hyun Jae; Kim, Soo Ok; Yoo, Wang Don; Han, KwangHyub.

In: The Korean journal of hepatology, Vol. 11, No. 2, 01.01.2005, p. 116-124.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association between CCR5 promoter polymorphisms and hepatitis B virus infection

AU - Chang, Hye Young

AU - Ahn, SangHoon

AU - kim, doyoung

AU - Shin, Jeon Soo

AU - Kim, Yong Soo

AU - Hong, Sun Pyo

AU - Chung, Hyun Jae

AU - Kim, Soo Ok

AU - Yoo, Wang Don

AU - Han, KwangHyub

PY - 2005/1/1

Y1 - 2005/1/1

N2 - BACKGROUND/AIMS: Immunogenetic factors may play a role in determining the susceptibility of an individual to viral infection. CCR5 promoter polymorphisms are known to be associated with HIV infection. However, there has been no report on the association between CCR5 promoter polymorphism and HBV infection. Therefore, we investigated the relationship between the CCR5 promoter polymorphism and HBV infection. METHODS: A total of 377 patients were classified into two groups according to their HBV infection status: (1) the spontaneous clearance group (SC); HBsAg (-), anti-HBc (+), anti-HBs (+) (2) the chronic HBsAg (+) carrier group (CC); HBsAg (+), anti-HBc (+), anti-HBs (-). CCR5 polymorphisms were detected by employing matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS)- based SNP scoring assay, termed Restriction Fragment Mass Polymorphism (RFMP), which exploits the differences in molecular masses between the common allele and rare allele bases of interest. RESULTS: We found that the genotype frequencies of CCR5 A59029G significantly differed between the SC group (n=138) and CC group (n=239) (P<0.05). The CCR5 59029A allelic genotype was associated with an increased risks of chronic infection rather than spontaneous clearance (P=0.002), and the presence of the CCR5 59029G allele was significantly associated with the spontaneous clearance of HBV (P=0.001). Strong linkage disequilibrium between the CCR5-59029 and the CCR5-59353 polymorphic variants was identified. None of the 377 subjects had the CCR5-32 bp deletion mutation. CONCLUSIONS: The CCR5 promoter polymorphisms at position 59029 might play a role in the clearance of HBV infection. This primary experimental evidence needs further studies to clarify the clinical usefulness of CCR5 promoter polymorphisms as a target for the screening or treatment of HBV infection.

AB - BACKGROUND/AIMS: Immunogenetic factors may play a role in determining the susceptibility of an individual to viral infection. CCR5 promoter polymorphisms are known to be associated with HIV infection. However, there has been no report on the association between CCR5 promoter polymorphism and HBV infection. Therefore, we investigated the relationship between the CCR5 promoter polymorphism and HBV infection. METHODS: A total of 377 patients were classified into two groups according to their HBV infection status: (1) the spontaneous clearance group (SC); HBsAg (-), anti-HBc (+), anti-HBs (+) (2) the chronic HBsAg (+) carrier group (CC); HBsAg (+), anti-HBc (+), anti-HBs (-). CCR5 polymorphisms were detected by employing matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS)- based SNP scoring assay, termed Restriction Fragment Mass Polymorphism (RFMP), which exploits the differences in molecular masses between the common allele and rare allele bases of interest. RESULTS: We found that the genotype frequencies of CCR5 A59029G significantly differed between the SC group (n=138) and CC group (n=239) (P<0.05). The CCR5 59029A allelic genotype was associated with an increased risks of chronic infection rather than spontaneous clearance (P=0.002), and the presence of the CCR5 59029G allele was significantly associated with the spontaneous clearance of HBV (P=0.001). Strong linkage disequilibrium between the CCR5-59029 and the CCR5-59353 polymorphic variants was identified. None of the 377 subjects had the CCR5-32 bp deletion mutation. CONCLUSIONS: The CCR5 promoter polymorphisms at position 59029 might play a role in the clearance of HBV infection. This primary experimental evidence needs further studies to clarify the clinical usefulness of CCR5 promoter polymorphisms as a target for the screening or treatment of HBV infection.

UR - http://www.scopus.com/inward/record.url?scp=33645645600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645645600&partnerID=8YFLogxK

M3 - Article

C2 - 15980670

AN - SCOPUS:33645645600

VL - 11

SP - 116

EP - 124

JO - Clinical and molecular hepatology

JF - Clinical and molecular hepatology

SN - 2287-2728

IS - 2

ER -